Get the Stockscreener App
1.77
1.72%
0.03
MAIA Biotechnology Inc stock is traded at $1.77, with a volume of 169.35K.
It is up +1.72% in the last 24 hours and down -0.56% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.74
Open:
$1.7
24h Volume:
169.35K
Relative Volume:
0.63
Market Cap:
$55.39M
Revenue:
-
Net Income/Loss:
$-25.94M
P/E Ratio:
-1.2826
EPS:
-1.38
Net Cash Flow:
$-15.79M
1W Performance:
-5.35%
1M Performance:
-0.56%
6M Performance:
-15.31%
1Y Performance:
-46.85%
1-Day Range:
$1.70
$1.8023
1-Week Range:
$1.60
$1.86
52-Week Range:
$1.40
$4.24
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.77 | 55.39M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
MAIA Biotechnology partners with Roche for cancer treatment studies By Investing.com - Investing.com South Africa
Maia Biotechnology Signs Clinical Supply Deal With Roche; Shares Rise - MarketScreener
MAIA Biotech (MAIA) Partners with Roche for Cancer Treatment Study - GuruFocus
MAIA Biotechnology, Inc. Announces Master Clinical Supply Agreement with Roche for Hard-To-Treat Cancer Therapies - marketscreener.com
MAIA Biotechnology in pact with Roche for cancer treatments - Seeking Alpha
MAIA Biotechnology partners with Roche for cancer treatment studies - Investing.com
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies - BioSpace
MAIA Biotechnology Announces Agreement with Roche - TipRanks
MAIA Biotechnology Enters Inducement Offer Agreements - TipRanks
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Declines By 35.8% - Defense World
MAIA Biotechnology to Present at BIO International Convention 2025 - BioSpace
Jane Street Group LLC Makes New Investment in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) - Defense World
MAIA Biotechnology Reports Positive Phase 2 Trial Results - TipRanks
Why Is MAIA Biotechnology Stock Trading Higher On Thursday?MAIA Biotechnology (AMEX:MAIA) - Benzinga
MAIA Biotechnology's Promising Results in Lung Cancer Trial | MA - GuruFocus
MAIA Biotechnology's Promising Results in Lung Cancer Trial | MAIA Stock News - GuruFocus
MAIA Biotechnology Says New Responder In Non-Small Cell Lung Cancer Phase 2 Clinical Trial - marketscreener.com
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial - Business Wire
MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer - BioSpace
MAIA Biotechnology Reports Promising Results from THIO-101 Phase 2 Trial | MAIA Stock News - GuruFocus
Maia Biotechnology Says Ateganosine Treatment Extends Median Overall Survival in Lung Cancer Study - marketscreener.com
Maia Biotechnology stock rises following positive trial results By Investing.com - Investing.com Nigeria
Maia Biotechnology stock rises following positive trial results - Investing.com Australia
MAIA Biotechnology Showcases Promising THIO-101 Trial Data - TipRanks
MAIA Biotechnology Announces Private Placement Agreement - TipRanks
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading 4.1% Higher – Still a Buy? - Defense World
MAIA Biotechnology secures $669,500 in private placement By Investing.com - Investing.com South Africa
MAIA Biotechnology Announces Private Placement of Approximately $669,500 - BioSpace
MAIA Biotechnology, Inc. (MAIA) Raises $695K in Private Placement to Advance Cancer Trial - Yahoo
CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000 - BioSpace
MAIA Biotechnology secures $669,500 in private placement - Investing.com
MAIA Biotechnology doubles authorized shares - Investing.com Australia
MAIA Biotechnology doubles authorized shares By Investing.com - Investing.com South Africa
MAIA Biotechnology Increases Authorized Common Stock Shares - TipRanks
MAIA Biotechnology Approves Key Changes at Annual Meeting - TipRanks
MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - Business Wire
MAIA Biotechnology Announces Director Participation in Recent Private Placement - Business Wire
Best Momentum Stocks to Buy for May 6th - The Globe and Mail
MAIA Biotechnology Raises $1.08M in Private Placement - TipRanks
MAIA Biotechnology launches $1.08M private placement - MSN
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement - Business Wire
MAIA Biotechnology secures $1.08 million in private placement By Investing.com - Investing.com Canada
Maia Biotechnology Announces $1.08 Million Private Placement - marketscreener.com
MAIA Biotechnology secures $1.08 million in private placement - Investing.com
MAIA Biotechnology Raises $1.08M at $1.50 Per Share to Advance Phase II Cancer Trial - Stock Titan
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
MAIA Biotechnology Inc Stock (MAIA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Guerrero Ramiro | Director |
May 08 '25 |
Buy |
1.50 |
20,000 |
30,000 |
588,218 |
| Smith Stan | Director |
May 08 '25 |
Buy |
1.50 |
66,666 |
99,999 |
1,271,726 |
| Guerrero Ramiro | Director |
Mar 03 '25 |
Buy |
1.50 |
33,333 |
50,000 |
568,218 |
| Smith Stan | Director |
Mar 03 '25 |
Buy |
1.50 |
25,000 |
37,500 |
1,205,060 |
| Guerrero Ramiro | Director |
Feb 24 '25 |
Buy |
1.50 |
73,333 |
110,000 |
534,885 |
| Smith Stan | Director |
Feb 24 '25 |
Buy |
1.50 |
50,000 |
75,000 |
1,180,060 |
| Smith Stan | Director |
Dec 13 '24 |
Buy |
1.87 |
25,000 |
46,800 |
1,130,060 |
| Guerrero Ramiro | Director |
Dec 13 '24 |
Buy |
1.87 |
53,418 |
99,998 |
514,970 |
| Luput Cristian | Director |
Nov 01 '24 |
Buy |
2.51 |
22,133 |
55,554 |
389,483 |
| CHAOUKI STEVEN M | Director |
Nov 01 '24 |
Buy |
2.51 |
22,133 |
55,554 |
111,024 |
1.11%
1.70%
Cap:
|
Volume (24h):